Home・Aandelen Lijst・Zoetis Inc

Zoetis Inc

Gesloten

SectorGezondheidszorg

75.98 -1.43

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

76.83

Max

79.78

Belangrijke statistieken
By Trading Economics
Inkomsten	-2M 601M
Verkoop	-125M 2.3B
K/W Sectorgemiddelde	12.61 64.641
EPS	1.53
Dividendrendement	2.69
Winstmarge	26.569
Werknemers	14,500
EBITDA	-8M 939M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+28.58% upside

Dividenden
By Acuity
Dividendrendement Sectorgemiddelde	2.69% 2.31%
Volgende Winsten	6 aug 2026
Volgende dividenddatum	1 sep 2026
Volgende Ex Dividend datum	30 okt 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-16B 32B
Vorige openingsprijs	77.41
Vorige sluitingsprijs	75.98

Nieuwssentiment

By Acuity

43%

57%

135 / 340 Rangschikking in Healthcare

Zoetis Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 aug 2026, 23:31 UTC

Zoetis Inc shares are higher in after-market trading, continuing positive momentum after three consecutive sessions of gains amid favorable market sentiment.

1 aug 2026, 00:01 UTC

Zoetis Inc shares rose in after-market trading, recovering from an initial dip and reaching a high near the upper end of its one-month range.

31 jul 2026, 23:06 UTC

Zoetis Inc shares are higher in after-market trading, maintaining gains since Friday's close and remaining above the 20-day moving average.

30 jul 2026, 19:03 UTC

Zoetis Inc shares are lower, impacted by a decline in the Pharmaceuticals sub-sector. Earlier in the session, the stock peaked before falling.

29 jul 2026, 22:51 UTC

Zoetis Inc shares are trading lower in after-market hours. No specific news was identified to explain the decline amid broader market volatility.

28 jul 2026, 23:02 UTC

Zoetis Inc shares are higher in after-market trading, reflecting broader market strength amid investor optimism ahead of key earnings reports and the Federal Reserve meeting.

27 jul 2026, 23:16 UTC

News

Zoetis shares are lower in after-market hours following a class action lawsuit alleging securities fraud and reduced profit guidance to between $6.85 and $7.00 per share.

25 jul 2026, 00:01 UTC

Zoetis Inc. shares are trading higher in after-market hours, continuing a positive trend after closing higher for three consecutive sessions.

24 jul 2026, 21:02 UTC

Zoetis Inc shares are higher in after-market trading, rebounding from an initial dip despite a broader market decline influenced by disappointing earnings from Tesla and Alphabet.

23 jul 2026, 20:02 UTC

Zoetis Inc. shares are higher as strength in the pharmaceuticals sub-sector drives upward momentum, contributing to modest gains since Wednesday's close.

22 jul 2026, 21:02 UTC

Zoetis Inc. shares are lower in after-market trading, continuing a trend of five consecutive daily declines amid mixed market performance and rising crude oil prices.

21 jul 2026, 17:51 UTC

News

Zoetis Inc. shares are lower amid scrutiny from a securities fraud class action lawsuit alleging undisclosed market share declines and safety issues with Librela.

20 jul 2026, 23:16 UTC

Zoetis shares traded higher in after-market hours, maintaining stability above Monday's close despite broader market pressures from rising treasury yields.

Peer Vergelijking

Prijswijziging

Zoetis Inc Prognose

Koersdoel

By TipRanks

28.58% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 99.38 USD 28.58%

Hoogste 130 USD

Laagste 85 USD

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor Zoetis Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

12 ratings

Buy

Hold

Sell

Gebaseerd op 12 analisten die aandelenratings hebben gegeven aan Zoetis Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

135 / 340 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Zoetis Inc

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.